当前位置: 首页 >> 检索结果
374. Disease burden attributable to intimate partner violence against females and sexual violence against children in 204 countries and territories, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Violence against women and against children are human rights violations with lasting harms to survivors and societies at large. Intimate partner violence (IPV) and sexual violence against children (SVAC) are two major forms of such abuse. Despite their wide-reaching effects on individual and community health, these risk factors have not been adequately prioritised as key drivers of global health burden. Comprehensive x§and reliable estimates of the comparative health burden of IPV and SVAC are urgently needed to inform investments in prevention and support for survivors at both national and global levels.
376. Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial.
作者: Lorenzo Falchi.;Marcel Nijland.;Huiqiang Huang.;Kim M Linton.;John F Seymour.;Rong Tao.;Michal Kwiatek.;Abel Costa.;Theodoros P Vassilakopoulos.;Richard Greil.;Ana Jiménez-Ubieto.;Shane A Gangatharan.;Ohad Benjamini.;Catherine Thieblemont.;Alessandra Tucci.;Anna Elinder-Camburn.;Arpad Illes.;Jan Novak.;Miguel A Pavlovsky.;Andrew McDonald.;Dok Hyun Yoon.;Dai Maruyama.;Gauri Sunkersett.;Jian P Mei.;Nabanita Mukherjee.;Feng Zhu.;Abualbishr Alshreef.;Elena Favaro.;Franck Morschhauser.; .
来源: Lancet. 2026年407卷10524期161-173页
An unmet need persists for chemotherapy-free regimens that induce durable responses for relapsed or refractory follicular lymphoma. Lenalidomide and rituximab (R2) is an accepted standard of care in this population. The EPCORE FL-1 trial aimed to evaluate the efficacy and safety of epcoritamab plus R2 versus R2 in participants with relapsed or refractory follicular lymphoma after at least one previous line of chemoimmunotherapy.
377. Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.
作者: Laurie H Sehn.;Kai Hübel.;Stefano Luminari.;Christian W Scholz.;Antonio Salar.;Shankara Paneesha.;Björn Engelbrekt Wahlin.;Panayiotis Panayiotidis.;Hui-Peng Lee.;Ana Jiménez-Ubieto.;Juan-Manuel Sancho.;Tae Min Kim.;Eva Domingo Domenech.;Takahiro Kumode.;Christina Poh.;Catherine Thieblemont.;Dries Deeren.;Edwin de Wit.;Michael Arbushites.;Irene Vassallo.;Marek Trneny.; .
来源: Lancet. 2026年407卷10524期133-146页
Follicular lymphoma is characterised by episodes of remission and relapse, with patients requiring multiple lines of therapy. Lenalidomide plus rituximab is a commonly used immunotherapy combination in patients with relapsed or refractory follicular lymphoma. We aimed to assess the efficacy and safety of adding tafasitamab, a CD19-targeted Fc-enhanced monoclonal antibody, to lenalidomide and rituximab in this setting.
|